胃癌新辅助治疗的进展
Progress in neoadjuvant therapy for gastric cancer.
作者信息
Su Peng-Fei, Yu Jian-Chun
机构信息
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.
出版信息
Oncol Lett. 2022 Jun;23(6):172. doi: 10.3892/ol.2022.13292. Epub 2022 Apr 13.
Abstract
Gastric cancer is one of the most common malignant tumor types in the world and the majority of patients have already reached the advanced stage at the time of initial diagnosis, owing to the subtle symptoms of gastric cancer in the early stage and the low rate of screening in the population. Surgical resection is one of the main treatments for advanced gastric cancer; however, the efficacy of surgery is limited by factors such as low radical resection rate and high distant metastasis rate. A large number of clinical trials have indicated that neoadjuvant therapy (NAT), which consists of neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and NAT combined with targeted therapy, may improve the therapeutic effect and prognosis of patients to different degrees. However, the benefit of NAT remains controversial due to the heterogeneity of clinical trials and gastric cancer itself. The present review summarizes the main research progress and key breakthrough of NAT for advanced gastric cancer and discusses its prospects.
摘要
胃癌是世界上最常见的恶性肿瘤类型之一，由于胃癌早期症状不明显且人群筛查率低，大多数患者在初次诊断时已处于晚期。手术切除是晚期胃癌的主要治疗方法之一；然而，手术疗效受到诸如根治性切除率低和远处转移率高等因素的限制。大量临床试验表明，新辅助治疗（NAT），包括新辅助化疗、新辅助放化疗以及NAT联合靶向治疗，可能在不同程度上改善患者的治疗效果和预后。然而，由于临床试验的异质性以及胃癌本身的特点，NAT的益处仍存在争议。本综述总结了晚期胃癌NAT的主要研究进展和关键突破，并探讨了其前景。
相似文献
1
Progress in neoadjuvant therapy for gastric cancer.胃癌新辅助治疗的进展
Oncol Lett. 2022 Jun;23(6):172. doi: 10.3892/ol.2022.13292. Epub 2022 Apr 13.
2
[Current status and prospect of perioperative therapy for locally advanced gastric cancer].[局部进展期胃癌围手术期治疗的现状与展望]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):101-106. doi: 10.3760/cma.j.cn.441530-20210105-00003.
3
Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines.基于美国国立综合癌症网络（NCCN）指南的变迁解读胃癌新辅助治疗的发展
World J Gastrointest Oncol. 2020 Jan 15;12(1):37-53. doi: 10.4251/wjgo.v12.i1.37.
4
Progress in the treatment of advanced gastric cancer.晚期胃癌治疗的进展
Tumour Biol. 2017 Jul;39(7):1010428317714626. doi: 10.1177/1010428317714626.
5
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].巩固性新辅助治疗或全新辅助治疗后低位直肠癌的保直肠手术：初步报告
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
6
[Effects of XELOX regimen as neoadjuvant chemotherapy on radical resection rate and prognosis in patients with advanced gastric cancer].[XELOX方案作为新辅助化疗对进展期胃癌患者根治性切除率及预后的影响]
Zhonghua Zhong Liu Za Zhi. 2013 Oct;35(10):773-7.
7
[Thinking of the application of membrane anatomy in gastric cancer surgery after neoadjuvant therapy].[新辅助治疗后膜解剖学在胃癌手术中的应用思考]
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Jul 25;23(7):657-660. doi: 10.3760/cma.j.cn.441530-20200430-00249.
8
[Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].奥沙利铂联合卡培他滨或奥沙利铂联合S-1新辅助化疗治疗进展期胃癌的安全性和有效性
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):138-144. doi: 10.3760/cma.j.cn.441530-20200721-00433.
9
[Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].[局部晚期高危直肠癌患者新辅助综合治疗的疗效与安全性分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007.
10
[Utilization of multimodal therapy concepts in stomach carcinoma in Germany].[德国胃癌多模式治疗理念的应用]
Zentralbl Chir. 2000;125(4):341-7.
引用本文的文献
1
Comparison of short- and long-term outcomes among total laparoscopic, laparoscopic-assisted, and open total gastrectomies for advanced gastric cancer patients after neoadjuvant chemotherapy: a multicenter retrospective cohort study.新辅助化疗后进展期胃癌患者全腹腔镜、腹腔镜辅助及开放全胃切除术的短期和长期结局比较：一项多中心回顾性队列研究
BMC Cancer. 2025 Aug 30;25(1):1401. doi: 10.1186/s12885-025-14765-x.
2
Role of Neoadjuvant Therapy in Remodeling Surgical Approaches for Gastrointestinal Malignancies.新辅助治疗在重塑胃肠道恶性肿瘤手术方式中的作用。
Curr Gastroenterol Rep. 2025 Jul 30;27(1):55. doi: 10.1007/s11894-025-01003-4.
3
Targeted therapies in neoadjuvant treatment for gastroesophageal cancer.食管癌新辅助治疗中的靶向治疗
Ecancermedicalscience. 2025 Jun 3;19:1921. doi: 10.3332/ecancer.2025.1921. eCollection 2025.
4
Current status and trends of machine learning applied in clinical research of gastric cancer from 2004 to 2023: global bibliometric and visual analysis.2004年至2023年机器学习在胃癌临床研究中的应用现状与趋势：全球文献计量与可视化分析
Front Oncol. 2025 May 6;15:1420517. doi: 10.3389/fonc.2025.1420517. eCollection 2025.
5
Chemotherapy Options for Locally Advanced Gastric Cancer: A Review.局部进展期胃癌的化疗方案综述
Cancers (Basel). 2025 Feb 26;17(5):809. doi: 10.3390/cancers17050809.
6
Novel computed tomography-based nomograms for the pretherapeutic prediction of response to neoadjuvant chemotherapy with S-1 and oxaliplatin with or without the addition of docetaxel in patients with advanced gastric cancer.基于新型计算机断层扫描的列线图，用于预测晚期胃癌患者接受含S-1和奥沙利铂、加或不加多西他赛的新辅助化疗的治疗前反应。
Quant Imaging Med Surg. 2024 Sep 1;14(9):6711-6723. doi: 10.21037/qims-24-748. Epub 2024 Aug 19.
7
MCM8 promotes gastric cancer progression through RPS15A and predicts poor prognosis.MCM8 通过 RPS15A 促进胃癌进展并预测不良预后。
Cancer Med. 2024 Jul;13(13):e7424. doi: 10.1002/cam4.7424.
8
Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients.深度学习列线图预测局部进展期胃癌患者新辅助化疗反应。
Abdom Radiol (NY). 2024 Nov;49(11):3780-3796. doi: 10.1007/s00261-024-04331-7. Epub 2024 May 26.
9
The application of radiomics in esophageal cancer: Predicting the response after neoadjuvant therapy.放射组学在食管癌中的应用：预测新辅助治疗后的反应。
Front Oncol. 2023 Apr 6;13:1082960. doi: 10.3389/fonc.2023.1082960. eCollection 2023.
本文引用的文献
1
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.接受 D2 胃切除术的局部晚期胃或胃食管交界腺癌患者中，围手术期或术后辅助奥沙利铂联合 S-1 与辅助奥沙利铂联合卡培他滨的比较（RESOLVE）：一项开放标签、优效性和非劣效性、III 期随机对照临床试验。
Lancet Oncol. 2021 Aug;22(8):1081-1092. doi: 10.1016/S1470-2045(21)00297-7. Epub 2021 Jul 9.
2
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.中国临床肿瘤学会（CSCO）：胃癌诊断与治疗临床诊疗指南，2021 年版。
Cancer Commun (Lond). 2021 Aug;41(8):747-795. doi: 10.1002/cac2.12193. Epub 2021 Jul 1.
3
Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.曲妥珠单抗联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛作为人表皮生长因子受体 2 阳性局部晚期胃食管腺癌患者的围手术期治疗：一项 Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer 研究组的 II 期试验。
Int J Cancer. 2021 Sep 15;149(6):1322-1331. doi: 10.1002/ijc.33696. Epub 2021 May 29.
4
The changing face of gastric cancer: epidemiologic trends and advances in novel therapies.胃癌的变化面貌：流行病学趋势与新型疗法的进展
Cancer Gene Ther. 2021 May;28(5):390-399. doi: 10.1038/s41417-020-00234-z. Epub 2020 Oct 2.
5
Targeted Therapies in Advanced Gastric Cancer.晚期胃癌的靶向治疗。
Curr Treat Options Oncol. 2020 Jul 28;21(9):70. doi: 10.1007/s11864-020-00774-4.
6
Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.阿帕替尼联合新辅助化疗后手术切除对局部进展期胃腺癌患者病理缓解的影响：一项单臂、开放标签、Ⅱ期临床试验。
Eur J Cancer. 2020 May;130:12-19. doi: 10.1016/j.ejca.2020.02.013. Epub 2020 Mar 11.
7
Trastuzumab Deruxtecan: First Approval.曲妥珠单抗-德鲁替康：首个获批
Drugs. 2020 Apr;80(5):501-508. doi: 10.1007/s40265-020-01281-4.
8
Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling.通过血清IgG糖组学分析预测局部晚期胃癌患者新辅助化疗疗效
Clin Proteomics. 2020 Feb 6;17:4. doi: 10.1186/s12014-020-9267-8. eCollection 2020.
9
Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.胃食管腺癌的基因组学和靶向治疗。
Cancer Discov. 2019 Dec;9(12):1656-1672. doi: 10.1158/2159-8290.CD-19-0487. Epub 2019 Nov 14.
10
Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma.18F-FDG PET/CT 评估局部晚期胃食管结合部腺癌新辅助放化疗的疗效。
Clin Nucl Med. 2020 Jan;45(1):38-43. doi: 10.1097/RLU.0000000000002840.
Zotero 插件